Huang Jianwen

黄建雯

Areas of practice

Ms. Jianwen Huang is a partner at the law firm of King & Wood Mallesons (KWM). Her main areas of practice are investment (domestic and outbound), mergers and acquisition (M&A) (domestic and cross-border M&A transactions), and general corporate matter.  She is also a leading partner in the KWM healthcare group. 

In 2015, Ms. Huang was selected as a highly recommended lawyer in the field of corporate M&A by Legal 500.  In 2011, Ms. Huang was awarded the Top 10 Outstanding Lawyer by the Beijing Bar Association.  Ms. Huang has won numerous awards from KWM including: 2015 Best Cross-Border Cooperation Award,  2012 Partner of the Year Award, 2010 Outstanding Partner Award, and 2006 Outstanding Lawyer Award.  Additionally, Ms. Huang represented Pfizer for Pfizer’s acquisition project, which was awarded the Cross-Border Deal of the Year and the Healthcare/Life Science Deal of the Year by M&A Advisor in 2010.

Investment and M&A (including FDI)

Ms. Huang has accumulated extensive experience in investment and M&A (including domestic and outbound investments as well as FDI) , and provided legal services to many multinational companies (including Fortune 500 companies), domestic companies, and state owned enterprises (SOEs) for their domestic investment and M&A projects.  Her legal services include complete architectural design of the investment and M&A transactions, due diligence, drafting and modifying transaction documents, negotiation, and assisting liaison with the government and assisting in the assessment and the approval of the governmental process.  Ms. Huang’s many years of professional experience has helped her familiarize herself with different company operation models, management models and concepts.  This helps her to provide the best advice to her clients for their M&A deals.  One of her representative matters is acting as GE’s counsel for Chinese law in GE’s acquisition of Alstom’s power and grid business, which is the biggest M&A deal in 2015 in the industry and the biggest industrial investment GE has ever made.

In addition, Ms. Huang has acted for various SOEs and domestic companies in multiple outbound investment and M&A projects, including acting as the lead counsel and successfully coordinating with attorneys from several countries and regions and different jurisdictions in completing outbound investment and M&A deals involving complicated transaction structure, tight timeline, complex approval process, and different types of target entity.  She has provided legal services for clients such as China General Nuclear Power Group, Aviation Industry Corporation of China International Holding Corporation and China Three Gorges International Corporation.  She has represented an SOE for its acquisition of mining projects in North America, Central Asia, Australia and Africa, including a series acquisition of publicly-traded companies in England and Australia and African subsidiaries.  This acquisition is the second biggest acquisition project in the global mining industry in that year. 

General Corporate Matter

Ms. Huang has an in-depth understanding of different industry background and unique models of corporate governance of clients (including multinational companies, SOEs and domestic companies), which allows her to provide targeted solution and help implement legal requirements during the process of setting up, operating and liquidation.  Ms. Huang’s services include, but are not limited to the provision of corporate governance structure and risk prevention structure advice, advise and consult with clients regarding the laws and regulations of the related industry, contract drafting, revising and negotiating, communication on behalf of the client with relevant government departments to obtain approval, and providing advisory services for the daily operation of clients’ respective businesses.   

Industry Focus

Ms. Huang acts for clients from varied industry backgrounds for their investment and M&A transactions.  The industries include pharmaceutical, medical, medical devices, food (including health food), agricultural products, cosmetics, direct marketing, clean energy (solar, wind and nuclear energy), machinery manufacturing, aerospace, mining, ports, telecommunications and other industries. 

As the leading partner of the KWM healthcare group, Ms. Huang has acted for a number of domestic and multinational pharmaceutical companies, medical device companies and medical institution investors with setting up, investment, mergers, daily operations and obtaining all types of relevant approvals (such as, product listed licensing, production and sales license).  Ms. Huang has also assisted with the liaison with the China Food and Drug Administration and the National Health and Family Planning Commission of the People’s Republic of China.  Ms. Huang is familiar with the regulatory supervision and registration requirements of drugs, food and cosmetics in China, and served as an expert witness regarding Chinese legal matters and provided opinions on Chinese laws in several oversea litigations involving health food.  Ms. Huang pays close attention to the latest developments in laws and regulations in medicine and medical related industries.  She is actively involved in the provision of legislative proposals, and is actively engaged with the relevant pharmaceutical industry association to provide legal consultancy services.     

Ms. Huang has served as legal counsel for SOEs and private enterprises that engage in the business of clean energy (including nuclear power, solar power and wind power) and mining.  She is quite familiar with the industrial traits, business models and clients’ needs in the energy industry and has provided legal services to clients for multiple domestic and cross-border acquisition projects.  

Publications

Ms. Huang has authored/co-authored a number of published books and articles related to FDI, cross-border investment, M&A, and the pharmaceuticals and healthcare industry, including:

  • 《Pharmaceuticals and the Law: A Guide to the Chinese Pharmaceuticals and Healthcare Market》;
  • 《European Lawyers’ Guide – Sales and Promotion of Drugs》 (first and second editions);
  • 《Foreign Investment Law Review》 (first and second editions);
  • 《China – Australia Free Trade Agreement Will Benefit You and Me – China-Australia Free Trade Agreement Guideline》 (joint publication of the Chinese Consulate General in Brisbane and KWM).
  • “Drug Listing Permit Holder System: Exploration”, China Legal Review (June 2016);
  • “Registration and Record Filing of Health Foods”, China AmCham Daily (8 March 2016);
  • “Obstacles Faced by Foreign Investment Projects”, China Law and Practice (November/December edition, 2014);
  • “How to Understand the Reformed Capital Registration System”, China Business Newspaper (29 May 2014);
  • “The Befuddling Aspects of Chinese Outbound Transactions in the Eyes of Non-Chinese Parties”, Asian-Mena Counsel (Volume 1, Issue 7, 2013);
  • “Recent Trends in China's Pharmaceutical Industry”, Asia Legal Business – China, (November edition, 2012).

In addition, Ms. Huang has published a series of articles on the KWM Law blog and KWM’s WeChat Platform on company law, foreign investment, food, health products, medicine, medical devices, cosmetic and medical industry related laws, regulations, policy interpretation and analysis of such industries.

Qualifications and Experience

Ms. Huang is a Chinese qualified lawyer.  Her working languages are Chinese and English.

Ms. Huang joined KWM in 2003.  Prior to joining the firm, she served as a lecturer at the Beijing Economics and Trade University School of Law, teaching Company Law.  She received her LL.M. from the New York University School of Law, her Master in Law from the City University of Hong Kong and was  a visiting scholar at the Harvard Law School.

Location

Legal insights

Stay Focused on the Policies of Hainan's Pharmaceutical and Healthcare Industry.

13 June 2018

The Draft incorporates and reflects material contents in the reform of drugs field in recent years.

31 October 2017

The Decisions has a significant impact on pharmaceutical companies.

16 October 2017

Comparison between the New and Old Catalogue for the Guidance of Foreign Investment Industries.

07 July 2017

This publication has been downloaded from the King & Wood Mallesons website. It is provided only for your information and does not constitute legal or other advice on any specific matter. If you require or seek legal advice you should obtain such advice from your own lawyer, and should do so before taking, or refraining from taking, any action in reliance on this publication. If you have any questions, please contact King & Wood Mallesons. See www.kwm.com for more information.